NCT06820463
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06820463
Title A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer (AndroMETa-CRC)
Acronym AndroMETa-CRC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors AbbVie
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ISR | GRC | FRA | ESP | CZE | AUT | AUS


No variant requirements are available.